Related Experiment Video
Updated: Aug 31, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Dynamic changes in soluble suppression of tumorigenicity 2 levels predict major adverse cardiovascular events in
Lei Liu1, Shengyu Li1, Xiaosong Ding1
1Department of Cardiology, Cardiovascular Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China
Insights
The increase in soluble suppression of tumorigenicity 2 (sST2) levels 24 hours after ST-segment elevation myocardial infarction (STEMI) treatment predicts adverse cardiovascular events. This finding aids in risk stratification for STEMI patients post-procedure.
Area of Science:
- Cardiology
- Biomarkers
- Myocardial Infarction Research
Background:
- Soluble suppression of tumorigenicity 2 (sST2) is a biomarker investigated for cardiovascular conditions.
- Its predictive value for major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients is not fully understood.
Purpose of the Study:
- To evaluate the role of sST2 in predicting MACEs in STEMI patients undergoing primary percutaneous coronary intervention (pPCI).
- To assess the dynamic changes of sST2 and other cardiac biomarkers in relation to MACEs.
Main Methods:
- A cohort of 350 STEMI patients treated with pPCI was studied.
- sST2, NT-proBNP, TnI, and CK-MB levels were measured at admission, 24 hours, and 5 days post-pPCI.
- MACEs were recorded as the primary endpoint.
Main Results:
- sST2 levels peaked at 24 hours post-pPCI and decreased by day 5.
- The change in sST2 from admission to 24 hours (Δ1sST2) was significantly higher in patients who experienced MACEs.
- Δ1sST2 independently predicted MACEs (AUC 0.621), with higher Δ1sST2 associated with increased MACEs, revascularization, and rehospitalization.
Conclusions:
- An increase in plasma sST2 from admission to 24 hours post-pPCI can independently predict 1-year outcomes.
- This dynamic change in sST2 may aid in predicting coronary revascularization and cardiac rehospitalization in STEMI patients.
Abstract:
Introduction：The predictive value of soluble suppression of tumorigenicity 2 (sST2) for the occurrence of major adverse cardiovascular events (MACEs) in patients with ST‑segment elevation myocardial infarction (STEMI) remains unclear.
Objectives:
We aimed to investigate the role of sST2 in predicting MACEs in STEMI patients after primary percutaneous coronary intervention (pPCI).
Patients And Methods:
A total of 350 patients were enrolled in this study. The levels of sST2, N‑terminal pro-B‑type natriuretic peptide (NT‑proBNP), cardiac troponin I (TnI), and creatine kinase-MB (CK‑MB) were measured on admission as well as 24 hours and 5 days after pPCI. The end point was the incidence of MACEs.
Results:
Compared with the values on admission, sST2 levels increased 24 hours post pPCI and decreased significantly at day 5 after the procedure in the whole cohort. The pattern of sST2 level changes between the 3 time points was similar in the MACE and MACE‑free groups. Notably, the change in the sST2 level from admission to 24 hours post pPCI (Δ1sST2) was significantly higher in the MACE group. After multivariable adjustment, Δ1sST2 was an independent risk factor for MACEs, with an area under the curve of 0.621 (95% CI, 0.547-0.695). Patients with a greater Δ1sST2 had a significantly higher incidence of composite MACEs, coronary revascularization, and cardiac rehospitalization. However, the change in sST2 levels from admission to 5 days post pPCI, as well as the dynamic changes in NT‑proBNP, TnI, and CK‑MB levels had no predictive value.
Conclusions:
The increase in plasma sST2 levels from admission to 24 hours post pPCI has a potential value for independently predicting the incidence of coronary revascularization and cardiac rehospitalization at 1 year in patients with STEMI.
More Related Videos
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Atherosclerosis III: Management
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:26Coronary Artery Disease II: Pathophysiology
01:30Coronary Artery Disease III: Clinical Manifestations